Currently, clopidogrel is recommended for treatment of patients with acute coronary
syndrome and/or percutaneous coronary intervention. However, the delayed onset of the …

MicroRNAs (miRNAs) are small, non-coding RNAs, able to regulate cellular functions by
specific gene modifications. Platelets are the major source for circulating miRNAs, with …

Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …

Content Clopidogrel, one of the most commonly prescribed medications, is a prodrug
requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on …

Context Clopidogrel therapy improves cardiovascular outcomes in patients with acute
coronary syndromes and following percutaneous coronary intervention by inhibiting …

Background Clopidogrel and prasugrel are subject to efflux via P-glycoprotein (encoded by
ABCB1, also known as MDR1). ABCB1 polymorphisms, particularly 3435C→ T, may affect …

Background Clopidogrel and low-dose aspirin have become the mainstay oral antiplatelet
regimen to prevent recurrent ischaemic events after acute coronary syndromes or stent …

Background—Both clopidogrel and prasugrel require biotransformation to active metabolites
by cytochrome P450 (CYP) enzymes. Among persons treated with clopidogrel, carriers of …

Objectives: The aim of this study was to assess the association between the loss-of-function
cytochrome P450 2C19 (CYP2C19)* 2 variant (10 studies, 11,959 patients) or the use of …

Despite initial enthusiasm, 1, 2, 3 the use of pharmacogenetics has remained limited to
investigation in only a few clinical fields such as oncology and psychiatry. 4, 5, 6, 7, 8 The …